Human Reproduction, Vol. 18, No. 11, 2315-2318,
November 2003
© 2003 European Society of Human Reproduction and Embryology
A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation
Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
1 To whom correspondence should be addressed at: 6/F, Professorial Block, Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, 102, Pokfulam Road, Hong Kong SAR, China. e-mail: ostang{at}graduate.hku.hk
BACKGROUND: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. This is the first randomized trial comparing the use of sublingual misoprostol with vaginal misoprostol in combination with mifepristone for termination of early pregnancies up to 63 days. METHODS: A total of 224 women who requested legal termination of pregnancy up to 63 days were randomized by computer- generated list into two groups and given 200 mg of oral mifepristone followed 48 h later by either 800 µg of sublingual (n = 112) or vaginal (n = 112) misoprostol. RESULTS: Complete abortion occurred in 98.2% (95% CI: 93–99) of women in the sublingual group and 93.8% (95% CI: 88–97) in the vaginal group. There were three ongoing pregnancies in the vaginal group but none in the sublingual group. The median duration of vaginal bleeding was 17 days. There was no serious complication. Fever, chills and gastrointestinal side-effects (nausea, vomiting and diarrhoea) were significantly more common in the sublingual group. CONCLUSIONS: The combination of mifepristone and misoprostol is effective for medical abortion up to 63 days. Both the sublingual and vaginal are effective routes of administration. Further randomized trials are required to find out the optimal dose of sublingual misoprostol that can give the highest complete abortion rate and lowest incidence of side-effects.
Key words: medical abortion/misoprostol/sublingual/vaginal
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. R. Meckstroth, A. K. Whitaker, S. Bertisch, A. B. Goldberg, and P. D. Darney Misoprostol Administered by Epithelial Routes: Drug Absorption and Uterine Response. Obstet. Gynecol., September 1, 2006; 108(3): 582 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. S. Tang, C. Y.T. Ong, K. Y. Tse, E. H.Y. Ng, S. W.H. Lee, and P. C. Ho A randomized trial to compare the use of sublingual misoprostol with or without an additional 1 week course for the management of first trimester silent miscarriage Hum. Reprod., January 1, 2006; 21(1): 189 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fiala, A. Aronsson, O. Stephansson, and K. Gemzell-Danielsson Effects of slow release misoprostol on uterine contractility in early pregnancy Hum. Reprod., September 1, 2005; 20(9): 2648 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hamoda, P. W. Ashok, G. M.M. Flett, and A. Templeton A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation Hum. Reprod., August 1, 2005; 20(8): 2348 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-U. Khan, H. El-Refaey, S. Sharma, D. Sooranna, and M. Stafford Oral, Rectal, and Vaginal Pharmacokinetics of Misoprostol Obstet. Gynecol., May 1, 2004; 103(5): 866 - 870. [Abstract] [Full Text] [PDF]
|
|